Dr. Xin Lu is John M. and Mary Jo Boler Associate Professor (endowed and tenured) at University of Notre Dame. The goal of Lu lab (https://biology.nd.edu/labs/lu-lab/) is to identify novel immuno-oncology targets and develop immunotherapies to benefit patients with metastatic cancers. We focus on both cancer cell intrinsic and extrinsic mechanisms of tumor immune evasion in a range of cancer types (e.g., prostate, breast, pancreas, kidney). Our research approach integrates genetically engineered mouse models, functional genomics, experimental therapeutics, and cutting-edge experimental and computational methodologies (single cell RNA-seq, spatial transcriptomics, high-throughput drug and CRISPR/cas9 screen, molecular digital pathology, multi-omics integration, etc.). Some recent publications include Wang*, Lu*, et al. Cancer Discovery, 2016 [PMID: 26701088]; Lu et al. Nature, 2017 [PMID: 28321130]; Feng…Lu, PNAS 2018 [PMID: 30232256]; Huang…Lu, Nat Comm, 2020 [PMID: 32358507]; Zhu…Lu, Science Immunology, 2023 [PMID: 36897957].
Located at the Department of Biological Sciences at the University of Notre Dame and affiliated with Indiana University Simon Comprehensive Cancer Center, Lu lab is seeking highly motivated Postdoctoral Fellow candidates with interests or expertise in areas such as:
• Cellular, biochemical or metabolic mechanism of cancer progression and metastasis
• Tumor microenvironment and immunology, tumor and immune metabolism, immunotherapy
• Cancer genomics, bioinformatics, single-cell RNA-seq, spatial transcriptomics, CRISPR screen
• Medicinal chemistry, chemical biology, tissue engineering, 3D tumor organoids
The lab research is actively supported by federal agencies and private foundations. A range of available projects include but are not limited to:
(1) Mechanistic understanding of immunosuppressive myeloid cells;
(2) Heterogeneity of MDSCs, neutrophils and other myeloid cells;
(3) Metabolic reprogramming to enhance cancer immunotherapy;
(4) Immunological regulation of cancer metastasis;
(5) Gene functions and therapy development for solid tumors;
(6) Novel 3D tumor organoids enabling high-throughput screening of immunotherapeutics.
Candidate should already hold or expected to hold a doctoral degree in molecular biology, biochemistry, cell biology, immunology, bioinformatics or related field. Experiences that are desirable (but not required) include mammalian cell culture, molecular cloning, cell biology and biochemistry assays, RNAi, CRISPR, immunology, animal models, histopathology, single-cell technology, or bioinformatics/computational biology. A notable publication record, effective communication skills and teamwork spirit are beneficial.
A generous offer package will be provided. University of Notre Dame is among the top 20 universities in the US ranked by US News. You will enjoy beautiful campus, safe and enriched environment and low-cost comfortable living style. Please kindly email current CV and names of 3 references to Dr. Xin Lu at XLU@ND.EDU.
Note: The University of Notre Dame is an Affirmative Action/Equal Opportunity Employer. Women and minority candidates are encouraged to apply.